Patents Assigned to Glycom A/S
  • Patent number: 11554131
    Abstract: The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2?-FL, LNnT, LNT, DFL, and 6?-SL.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: January 17, 2023
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell, Kristine Rothaus Christensen
  • Patent number: 11541068
    Abstract: The invention relates to human milk oligosaccharides (HMO) and its use in treatment of autism spectrum disorder (ASD).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 3, 2023
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 11541067
    Abstract: A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful for the treatment of brain-gut disorders like autism, stress, anxiety, and depressive disorders, are disclosed. Methods of treatment of colon cancer and liver damage are also disclosed.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 3, 2023
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell
  • Patent number: 11541069
    Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in reducing or preventing fatigue and/or improving focus or concentration on a mental or physical activity in a human. The invention also relates to a synthetic composition for use, comprising one or more of said HMOs. The invention further relates to a method for reducing or preventing fatigue and/or improving focus or concentration on a mental or physical activity by administering at least one HMO and the use of said one or more HMOs in a dietary management of a human.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 3, 2023
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, Ingvild Dybdrodt Amundsen
  • Patent number: 11529364
    Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Glycom A/S
    Inventors: Emma Elison, Bruce McConnell, Thierry Hennet, Louise Kristine Vigsnæs
  • Patent number: 11529365
    Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: December 20, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 11524019
    Abstract: This invention relates to a method and composition for inducing allergen tolerance in a patient suffering from an atopic allergy or allergic asthma; hence reducing allergy symptoms in these patients.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: December 13, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 11505567
    Abstract: It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 22, 2022
    Assignee: GLYCOM A/S
    Inventors: Benjámin Podányi, Pierre Chassagne, Martin Matwiejuk, Markus Jondelius Hederos
  • Patent number: 11491171
    Abstract: A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: November 8, 2022
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
  • Patent number: 11432578
    Abstract: A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2?-fucosyllactose (2?FL), 3?-O-sialyllactose (3?-SL), 6?-O-sialyllactose (6?-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: September 6, 2022
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vignæs
  • Patent number: 11419884
    Abstract: The present disclosure relates to synthetic mixtures of certain human milk oligosaccharides and uses thereof. Particular mixtures provided herein include: lacto-N-triose II, lacto-N-neotetraose, para-lacto-N-neohexaose, and, optionally, lactose; and lacto-N-triose II, lacto-N-tetraose, para-lacto-N-hexaose II, and, optionally, lactose. These mixtures are useful in the prevention and treatment of viral and bacterial infections.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: August 23, 2022
    Assignee: GLYCOM A/S
    Inventors: Nikolay Khanzhin, Markus Jondelius Hederos, Louise Kristine Vigsnæs, Bruce McConnell
  • Patent number: 11384110
    Abstract: The present invention relates to a method of removing residual organic solvent from crystalline oligosaccharides by the use of water vapour as well as the pharmaceutically and nutritionally suitable crystalline oligosaccharides obtained by said method.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: July 12, 2022
    Assignee: GLYCOM A/S
    Inventors: Pierre Chassagne, Martin Matwiejuk, Nikolay Khanzhin, Markus Jondelius Hederos
  • Patent number: 11312741
    Abstract: The invention relates to a method for obtaining an N-acetylglucosamine containing neutral oligosaccharide from a fermentation broth, wherein said oligosaccharide is produced by culturing a genetically modified microorganism capable of producing said oligosaccharide from an internalized carbohydrate precursor, comprising the steps of: i) ultrafiltration (UF), preferably to separate biomass from the broth, ii) nanofiltration (NF), preferably to concentrate said oligosaccharide in the broth and/or reduce an inorganic salt content of the broth, and iii) treating the broth with an ion exchange resin, preferably to remove charged materials, and/or subjecting the broth to chromatography, preferably to remove hydrophobic impurities.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: April 26, 2022
    Assignee: GLYCOM A/S
    Inventors: Pierre Chassagne, Nikolay Khanzhin, Martin Matwiejuk, Markus Jondelius Hederos, Niels Banke
  • Patent number: 11304966
    Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 19, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, Sami Damak, Norbert Sprenger, Francis Foata
  • Patent number: 11293042
    Abstract: The invention relates to a genetically modified microorganism for making a oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: April 5, 2022
    Assignee: GLYCOM A/S
    Inventors: Margit Pedersen, Manos Papadakis, Peter Becker, Eric Samain, Pauline Peltier-Pain, Katrine Bych, Ted Johanson, Elise Champion, Gyula Dekany
  • Patent number: 11291677
    Abstract: The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the level of butyrate in the gastro-intestinal tract of the non-infant human, and methods for their use.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: April 5, 2022
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell
  • Patent number: 11278558
    Abstract: The invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans, particularly for increasing the abundance of Bifidobacterium longum and/or Bifidobacterium bifidum in the gut microbiota of non-infant humans.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 22, 2022
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell
  • Patent number: 11267839
    Abstract: The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: March 8, 2022
    Assignee: GLYCOM A/S
    Inventors: Martin Matwiejuk, Pierre Chassagne, Markus Jondelius Hederos
  • Patent number: 11224605
    Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for treating serotonin and/or tryptophan dysregulation.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 18, 2022
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell, Emma Elison
  • Patent number: 11214588
    Abstract: This invention relates to a method for the enzymatic synthesis of oligosaccharides, preferably human milk oligosaccharides (HMOs) The method comprises the enzymatic transfer of a glycosyl moiety and subsequent removal of by-products, such as lactose, by nanofiltration using a membrane comprising an active polyamide layer.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: January 4, 2022
    Assignee: GLYCOM A/S
    Inventors: Nikolay Khanzhin, Markus Jondelius Hederos